about
Role of cytochrome P450 in drug interactionsRoles of rifampicin in drug-drug interactions: underlying molecular mechanisms involving the nuclear pregnane X receptor.Pharmacokinetic drug-drug interaction and their implication in clinical managementPharmacokinetics of antituberculosis drugs in pulmonary tuberculosis patients with type 2 diabetesRegulation of endoplasmic reticulum biogenesis in response to cytochrome P450 overproduction.Tuberculosis and diabetes mellitus - an underappreciated association.Receptor-dependent transcriptional activation of cytochrome P4503A genes: induction mechanisms, species differences and interindividual variation in man.Induction of theophylline clearance by rifampin and rifabutin in healthy male volunteers.Multiple-dose pharmacokinetics of ritonavir in human immunodeficiency virus-infected subjectsPharmacokinetics of isoniazid, rifampin, and pyrazinamide in children younger than two years of age with tuberculosis: evidence for implementation of revised World Health Organization recommendations.Concentrations and effects of buspirone are considerably reduced by rifampicinInfluence of rifampin on fleroxacin pharmacokinetics.Effects of rifampin and multidrug resistance gene polymorphism on concentrations of moxifloxacinEffect of rifampicin on the pharmacokinetics and pharmacodynamics of glimepiride.The pregnane X receptor in tuberculosis therapeutics.The effect of CYP3A inhibitors and inducers on the pharmacokinetics of telaprevir in healthy volunteersConcurrent assessment of hepatic and intestinal cytochrome P450 3A activities using deuterated alfentanilHepatic drug-metabolizing enzyme induction and implications for preclinical and clinical risk assessment.Staphylococcus aureus-Associated Musculoskeletal Infections.Pharmacokinetic interaction between rifampin and zidovudine.A simultaneous assessment of CYP3A4 metabolism and induction in the DPX-2 cell line.Effect of rifampicin pretreatment on the oral bioavailability of domperidone in healthy human volunteers.Effects of benzimidazole derivatives on cytochrome P450 1A1 expression in a human hepatoma cell line.Marked enhancement by rifampicin and lack of effect of isoniazid on the elimination of quinine in man.Influence of drugs interacting with CYP3A4 on the pharmacokinetics, pharmacodynamics, and safety of the prandial glucose regulator repaglinide.Lack of enzyme-inducing effect of rifampicin on the pharmacokinetics of enfuvirtide.The Bidirectional Relationship between Tuberculosis and Diabetes.Characterization of cytochrome P450 (CYP3A12) induction by rifampicin in dog liver.Effect of multiple doses of rifampin on the [14C N-methyl] erythromycin breath test in healthy male volunteers.Quantitation of cytochrome P450 enzymes (CYP1A1/2, 2B11, 2C21 and 3A12) in dog liver microsomes by enzyme-linked immunosorbent assay.Effect of rifampin on plasma concentrations of mefloquine in healthy volunteers.Use of salivary caffeine tests to assess the inducer effect of a drug on hepatic metabolism.
P2860
Q21245066-2A3F98C8-B1FD-444E-B389-0BACED909E49Q25255438-AFB433F4-033B-4513-8A63-DF0B3F4178EAQ27021051-BE1DFF9E-3386-46A1-98C9-9219177F2BEBQ33521011-625B6C21-72B3-4E53-B453-687C0F9600EFQ33639751-2E0F11FD-A5F7-49E5-B3CA-135CF5DF92FDQ34466787-70BF34A4-3113-4E98-874C-44F7C0E4BE8DQ34604457-3C135636-C13F-48A9-ABE3-B881B6C855E5Q35126115-DED099F1-3990-4A46-85B5-8699089404AFQ35135626-921CA6C1-4420-41D7-B6BE-A1D4557A918BQ35598492-784C1FC0-3A40-4BC5-84BF-26EE894B67CBQ35802991-EBEBCBCB-4CA9-4389-B023-5159528B3672Q35897356-E975E126-617F-4637-94A9-F2EFBE601003Q35912661-73F94A29-58A3-42CC-B5F1-6A4BFF857E2FQ36055344-E4E236D5-B833-4B4B-9255-4E15DE7505CFQ36451492-EA90BAF5-8686-4494-A855-7FD825EC27C2Q36629222-0523AC45-D2FD-472B-A247-4546E448D6BAQ36646017-71BB9B8C-45CA-40FD-AE52-E5C2D151CB7CQ37771144-5DDD5C0D-7A74-4D81-9B38-B9E27972610EQ39092499-B74C6E38-24CB-47C5-9F49-0B51045AEF78Q39866285-6EF7A770-8DED-48AE-8919-616BF38C3214Q40376556-0673652E-E574-4C02-9B72-A5CF027894DAQ41008408-6E320B24-7082-4053-89FC-1E960E198224Q41141334-E26643C8-6C9C-4278-87B9-0F86B4BC8C03Q42144199-63D43202-EBAC-4762-BB89-BD77DCF1696FQ44484818-CE934990-3235-4F52-858A-265909C84A61Q44654377-52DE65F2-DC38-439D-9D4C-0C394D75DF1FQ47160485-53A5C26E-7412-417F-B351-C3A5FACF4409Q47832946-A94616A4-8AA3-469F-8443-88E026C25AA8Q47896238-A700A1D8-381B-4D68-B316-C2703FDAE57CQ52200820-D6DD6EFB-7885-461E-920A-1215D095DA2EQ53901250-B050FBC0-4803-47A0-9A93-C24B69BD52F9Q53985559-35548BA2-D508-4E7D-86D1-7CD724A4A34E
P2860
description
1992 nî lūn-bûn
@nan
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
1992年论文
@zh
1992年论文
@zh-cn
name
Pharmacokinetic drug interactions with rifampicin.
@ast
Pharmacokinetic drug interactions with rifampicin.
@en
type
label
Pharmacokinetic drug interactions with rifampicin.
@ast
Pharmacokinetic drug interactions with rifampicin.
@en
prefLabel
Pharmacokinetic drug interactions with rifampicin.
@ast
Pharmacokinetic drug interactions with rifampicin.
@en
P1476
Pharmacokinetic drug interactions with rifampicin.
@en
P2093
Venkatesan K
P356
10.2165/00003088-199222010-00005
P577
1992-01-01T00:00:00Z
P6179
1051476625